PARIS, Jan 8, 2026, 20:02 (CET) — Market closed
Shares in French biotech Abivax SA (ABVX.PA) closed down 9.49% at 99.20 euros on Thursday, after swinging between 112.40 euros at the open and a low of 94.20 euros. The stock slipped back under the 100-euro mark, with volume at about 246,000 shares, after a 6% rise the day before. 1
The selling pressure comes as investors look ahead to key readouts for obefazimod, Abivax’s lead drug candidate for ulcerative colitis, a chronic inflammatory bowel disease. Abivax has told investors topline results from its Phase 3 maintenance study are expected in late Q2 2026, with a U.S. regulatory filing planned later in 2026. 2
With no marketed product, the stock trades on milestones and sentiment. Fresh supply from big holders can move it fast, even on days with little new clinical data.
A U.S. Form 144 filing showed shareholder Sofinnova Crossover I SLP intends to sell up to 1,000,000 American depositary shares (ADS) through Leerink Partners on Nasdaq, with an indicated aggregate market value of $133.7 million. Rule 144 is an SEC rule that sets conditions for resales of restricted or “control” stock; a notice signals intent but does not guarantee a sale. 3
BTIG analyst Julian Harrison raised his price target on Abivax to $150 from $120 and kept a “Buy” rating, according to a report published on Thursday. 4
But the same setup that fuels sharp rallies can cut the other way. If more stock hits the market, it can cap rebounds, and any slip in trial timelines — or an efficacy or safety disappointment — would likely reset expectations quickly.
